| Grab Sources And More Here: Company Website. Company Presentation. -----
As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out:
#1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 700% Potential Upside From MAIA's Current Chart Levels.
Recently, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA.
From Tuesday's closing valuation, that provides MAIA with upside potential well over 700%!
Check out some key report highlights:
Conclusion. Roche becomes the third pharmaceutical company to make a supply agreement with MAIA to test a checkpoint inhibitor in combination with THIO. We believe this shows that potential partners have noticed the data showing improved overall survival (OS), progression free survival (PFS), and the side effect profile. Clinical data from the three of the eight approved checkpoint inhibitors could make bidding for a marketing partnership more competitive. We are reiterating our Outperform rating and $14 price target. -----
#2. MAIA Potential Catalyst - Volatility Could Be In Full Force Based On MAIA's Low Float.
According to info from the Yahoo Finance website, MAIA has a relatively low float.
The website reports this profile to have roughly 28.34Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
Could even more positive company news in the 2nd half of 2025 provide a breakout spark when paired with this volatility potential? -----
#3. MAIA Potential Catalyst - Another Analyst Target Suggests Over 500% Potential Upside From Tuesday's Close.
Last month, an analyst at Diamond Equity Research provided an update on their (NYSE: MAIA) coverage.
In the update, they tagged MAIA with a target of $10.27.
From Tuesday's close, that target provides MAIA with a potential upside of over 500%.
Here's some highlights from the report:
Valuation: Recent updates further de-risk the THIO program in third-line NSCLC. The Phase 2 THIO-101 dataset now shows a median overall survival of 17.8 months in the intent-to-treat cohort with a generally tolerable safety profile, and a confirmed partial response after 20 months of therapy supports durability. Fast Track designation for ateganosine in NSCLC and a master clinical supply agreement with Roche to evaluate the THIO–atezolizumab sequence enhance the regulatory path and partnering visibility. We continue to expect initiation of the pivotal THIO-104 study in the second half of 2025 with an accelerated approval filing targeted for 2026, contingent on THIO-101 outcomes, while planned multitumor studies expand the addressable opportunity. We have revised our valuation model to incorporate the most recent financial results, updated share count, and re-evaluated the comparable company analysis, yielding a valuation of $10.27 per share, contingent on successful execution by the company. -----
#4. MAIA Potential Catalyst - MAIA Receives A Key Grant From The NIH For Phase 2 THIO-101 Trial.
MAIA Biotechnology Awar-ded $2.3Mn Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC)
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), ..., announced today that the National Institutes of Health (NIH) has awar-ded a $2.3Mn grant for the expansion of its THIO-101 Phase 2 clinical trial evaluating ateganosine as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC).
The grant is intended to support expenses related to the enrollment of U.S. patients who are resistant to chemo and immunotherapy. The NIH grant allocations will be distributed over three years from 2025-2027.
“We are thrilled to receive this prestigious NIH grant for the expansion of our Phase 2 trial. It’s a great honor to have the support of the National Institutes of Health as we seek to further validate the efficacy of our lead agent ateganosine and its potential to be a breakthrough treatment within the vastly underserved NSCLC market,” said CEO Vlad Vitoc, M.D. “With the clearance of FDA Investigational New Drug (IND) for THIO-101 in 2023, we can begin enrolling U.S. patients in the expansion phase of the trial immediately.”
“The NIH grant is a tremendous achievement and a testament to the dedication, collaboration, and hard work of everyone involved in the clinical development of ateganosine,” added Victor Zaporojan, M.D., MAIA’s senior medical director. “Ateganosine represents a potential solution for the significant unmet clinical need in third-line NSCLC, where no established standard of care exists and where the overall survival outcomes observed with ateganosine have not been achieved by other therapies. By enrolling patients in the United States, our trial will gain access to a substantially larger patient pool across multiple continents, further strengthening the impact and relevance of our study.”
...
Read the full article here. -----
#5. MAIA Potential Catalyst - An Important Milestone Is Reached In Company Receiving FDA Fast Track Designation For Ateganosine.
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
Potential first-to-market small molecule telomere targeting agent targets a $34Bn NSCLC treatment market
Latest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 months
CHICAGO, July 28, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor.
...
"FDA’s Fast Track Designation recognizes ateganosine’s potential as a new therapeutic paradigm in cancer treatment science. Ateganosine is the first and only anticancer treatment of its kind that we are aware of in clinical development," stated MAIA Chairman and CEO Vlad Vitoc, M.D. "If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. If approved, ateganosine would have a first-to-market competitive position within a $34Bn NSCLC treatment market with significant unmet medical need."
...
"This is an important milestone for MAIA’s clinical development program. Ateganosine has demonstrated robust preclinical efficacy and superior clinical median overall survival compared to other FDA-approved treatments for NSCLC patients with prior disease progression on platinum-based chemotherapy and anti-PD-(L)1 antibody. Additionally, advanced NSCLC is a devastating disease that clearly meets the criteria for a serious condition with unmet medical need. Both are key criteria for the Fast Track designation," said K. Robinson Lewis, Vice President, Head of Regulatory and Quality at MAIA. "We intend to utilize the incentives of the Fast Track Program to expedite the development and review of ateganosine and bring patient access sooner."
...
Read the full article here. -----
MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts
#1. One Analyst's Target Suggests Over 700% Potential Upside From MAIA's Current Chart Levels.
#2. Volatility Could Be In Full Force Based On MAIA's Low Float.
#3. Another Analyst Target Suggests Over 500% Potential Upside From Tuesday's Close.
#4. MAIA Receives A Key Grant From The NIH For Phase 2 THIO-101 Trial.
#5. An Important Milestone Is Reached In Company Receiving FDA Fast Track Designation For Ateganosine. -----
Coverage is officially reinitiated on (NYSE American: MAIA). When updates are available, I'll get them out quickly. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/30/2025 and ending on 10/01/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred thirty eight thousand seven hundred fifty USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/maia-6u8nz/#details | 
